HomeCompareACRX vs BTI

ACRX vs BTI: Dividend Comparison 2026

ACRX yields 232.56% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACRX wins by $293.63M in total portfolio value
10 years
ACRX
ACRX
● Live price
232.56%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$293.67M
Annual income
$159,094,488.39
Full ACRX calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — ACRX vs BTI

📍 ACRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACRXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACRX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACRX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACRX
Annual income on $10K today (after 15% tax)
$19,767.44/yr
After 10yr DRIP, annual income (after tax)
$135,230,315.13/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, ACRX beats the other by $135,227,933.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACRX + BTI for your $10,000?

ACRX: 50%BTI: 50%
100% BTI50/50100% ACRX
Portfolio after 10yr
$146.85M
Annual income
$79,548,645.33/yr
Blended yield
54.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ACRX
Analyst Ratings
10
Buy
6
Hold
1
Sell
Consensus: Buy
Altman Z
-22.3
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACRX buys
0
BTI buys
0
No recent congressional trades found for ACRX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACRXBTI
Forward yield232.56%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$293.67M$37.8K
Annual income after 10y$159,094,488.39$2,802.29
Total dividends collected$278.92M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ACRX vs BTI ($10,000, DRIP)

YearACRX PortfolioACRX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$33,956$23,255.81$11,301$601.08+$22.7KACRX
2$110,134$73,800.94$12,799$706.58+$97.3KACRX
3$341,552$223,709.32$14,527$832.38+$327.0KACRX
4$1,013,853$648,391.74$16,527$982.75+$997.3KACRX
5$2,883,575$1,798,752.11$18,846$1,162.95+$2.86MACRX
6$7,866,701$4,781,276.29$21,545$1,379.49+$7.85MACRX
7$20,607,870$12,190,500.18$24,694$1,640.41+$20.58MACRX
8$51,895,877$29,845,455.63$28,378$1,955.69+$51.87MACRX
9$125,770,153$70,241,564.71$32,702$2,337.79+$125.74MACRX
10$293,668,552$159,094,488.39$37,794$2,802.29+$293.63MACRX

ACRX vs BTI: Complete Analysis 2026

ACRXStock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Full ACRX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ACRX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACRX vs SCHDACRX vs JEPIACRX vs OACRX vs KOACRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.